Aligos Therapeutics, Inc.
ALGSAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| May 21, 2026 | Cantor Fitzgerald | $20.00(+257%) | $5.60 | TheFly | |
| Jan 7, 2026 | UBS | Michael Yee | $20.00(+128%) | $8.76 | StreetInsider |
| Jan 6, 2023 | Piper Sandler | $3.00(+147%) | $1.22 | Benzinga | |
| Jan 6, 2023 | Jefferies | $3.00(+203%) | $0.99 | Benzinga |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| HC Wainwright & Co. | maintain | Buy | Mar 11, 2026 |
| HC Wainwright & Co. | maintain | Buy | Sep 12, 2025 |
| HC Wainwright & Co. | maintain | Buy | Mar 31, 2025 |
| HC Wainwright & Co. | maintain | Buy | Mar 11, 2025 |
| HC Wainwright & Co. | maintain | Buy | Nov 7, 2024 |
| HC Wainwright & Co. | maintain | Buy | Oct 23, 2024 |
| HC Wainwright & Co. | maintain | Buy | Sep 20, 2024 |
| Piper Sandler | maintain | Overweight | Jan 17, 2023 |
| Jefferies | upgrade | Hold →Buy | Jan 6, 2023 |
| Piper Sandler | upgrade | Neutral →Overweight | Jan 6, 2023 |
| SVB Leerink | maintain | Market Perform | Nov 3, 2022 |
| SVB Leerink | downgrade | Outperform →Market Perform | May 5, 2022 |
| SVB Leerink | maintain | Outperform | Mar 23, 2022 |
| Piper Sandler | downgrade | Overweight →Neutral | Mar 23, 2022 |
| SVB Leerink | maintain | Outperform | Mar 11, 2022 |
| Piper Sandler | maintain | Overweight | Mar 11, 2022 |
| SVB Leerink | maintain | Outperform | Feb 16, 2022 |
| SVB Leerink | maintain | Outperform | Jan 7, 2022 |
| JP Morgan | downgrade | Overweight →Neutral | Jan 7, 2022 |
| SVB Leerink | maintain | Outperform | Sep 9, 2021 |
| JP Morgan | maintain | Overweight | Nov 10, 2020 |
| Piper Sandler | maintain | Overweight | Nov 10, 2020 |
| Jefferies | maintain | Buy | Nov 10, 2020 |
Earnings History
Next report: Mar 4, 2027 · EPS est. $-1.91| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Nov 6, 2026 | $-2.09 | $-2.28 | $2.9M | $4.8M |
| Aug 6, 2026 | $-0.14 | $-1.09 | $27.8M | $24.7M |
| May 7, 2026 | $-2.21 | $-2.29 | $2.8M | $250.0K |
| Mar 5, 2026 | $-1.91 | $-2.49 | $169.0K | $440.0K |
| Nov 6, 2025 | $-3.04 | $-2.09 | $741.0K | $266.7K |
| Aug 6, 2025 | $-1.53 | $-2.35 | $965.0K | $433.3K |
| May 6, 2025 | $-2.11 | $-2.80 | $311.0K | $500.0K |
| Mar 10, 2025 | $-13.08 | $-2.63 | $629.0K | $433.3K |
News
SOUTH SAN FRANCISCO, Calif., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today reported recent business progress and financial results for the third quarter 2026.
SOUTH SAN FRANCISCO, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced positive data from five presentations at the American Association for the Study of Liver Disease's (AASLD) The Liver Meeting® 2026, being held November 5 – 9, 2026 in Denver, CO.
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced that it will host an investor call on Monday, October 12, 2026 at 8:
SOUTH SAN FRANCISCO, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced five abstracts have been accepted for presentation at the American Association for the Study of Liver Disease's (AASLD) The Liver Meeting® 2026, being held November 5 – 9, 2026 in Denver, CO. The abstracts released today can be found on…
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced that it will host an investor call on Monday, September 28, 2026 at
Aligos Therapeutics (NASDAQ: ALGS - Get Free Report) and Voyager Therapeutics (NASDAQ: VYGR - Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, analyst recommendations and earnings. Institutional and Insider Ownership 60.4% of Aligos
Bank of America Corp DE grew its holdings in shares of Aligos Therapeutics, Inc. (NASDAQ: ALGS) by 1,652.8% in the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 229,754 shares of the company's stock after buying an additional 216,646 shares
SOUTH SAN FRANCISCO, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that members of management will present at the Cantor Global Healthcare Conference.
SOUTH SAN FRANCISCO, Calif., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that dosing has been initiated in the Phase 1 study of ALG-170675, an investigational next-generation antisense oligonucleotide (ASO) being evaluated for functional cure in the treatment of chronic hepatitis B virus (HBV) infection. The stu…